Avacta to Present Pre-Clinical Data on AVA3996 at the American Association for Cancer Research Annual Meeting

Avacta Group plc, a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces it will present a poster entitled ?AVA3996, a novel pre|CISIONtm medicine, targeted to the tumor microenvironment via Fibroblast Activation Protein-alpha (FAP-a) mediated cleavage', at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place at Orange County Convention Center, Orlando, Florida on 16 April.

The poster describes the data and pre-clinical rationale for the further development and disease positioning of the Company's second pre|CISIONtm candidate, AVA3996, a tumour microenvironment activated proteasome inhibitor. AVA3996 utilises Avacta's pre|CISIONtm platform to improve the therapeutic index and therefore utility of proteasome inhibitors in tumours with high FAP levels, including both solid and haematological tumours. AVA3996 has the potential to deliver efficacious levels of the proteasome inhibitor warhead directly to the tumour microenvironment while reducing systemic exposure and hence associated toxicities, such as peripheral neuropathy.

Attending the conference from Avacta will be Fiona McLaughlin ? Chief Scientific Officer, Neil Bell ? Chief Development Officer, David Jones ? VP Biology and Francis Wilson ? VP Chemistry.

The abstract is available via the AACR annual meeting website, here: https://www.abstractsonline.com/pp8/#!/10828/presentation/2606

Copies of the poster will be available on Avacta's website following the conference at: https://avacta.com/about/resources/posters/

Alastair Smith, Avacta Chief Executive Officer, will provide a video presentation overview for investors examining the data presented in the poster. This will be available on 17th April at https://avacta.com/investors/documents-presentations/